Moreover, PRMT1 inhibitors can remodel the tumor microenvironment by augmenting the quantity and functionality of CD8+ T cells, suppressing tumor proliferation, and restoring the efficacy of PD‐1 checkpoint blockade in resistant melanoma [58]. This evidence concerns the gene CD8A and neoplasm.